Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 1077-1085

  Kaplan, Barbara L Faubert ^a   Rockwell, Cheryl E ^a   Kaminski, Norbert E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CALCIUM; CALCIUM IONOPHORE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 2; PERTUSSIS TOXIN; PHORBOL ESTER; RIMONABANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOMODULATION; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CALCIUM; CANNABIDIOL; DRUG INTERACTIONS; FEMALE; INTERLEUKIN-2; LEUKOCYTES; MICE; MORPHOLINES; NAPHTHALENES; PERTUSSIS TOXIN; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRADECANOYLPHORBOL ACETATE;

EID: 0042934012     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.051961     Document Type: Article

References (37)

1. Berdyshev EV (2000) Cannabinoid receptors and the regulation of immune response. Chem Physiol Lipids 108:169-190.
2. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, LeFur G, and Casellas P (1993) Cannabinoid-receptor expression in human leukocytes. Eur J Pharmacol 214:173-180.
3. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, and Glass M (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396:141-149.
4. Cantrell D (1996) T cell antigen receptor signal transduction pathways. Annu Rev Immunol 14:259-274.
5. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, Bouaboula M, Galiegue S, Mondiere P, Penarier G, et al. (1998) Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92:3605-3615.
6. Condie R, Herring A, Koh WS, Lee M, and Kaminski NE (1996) Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin-2 (IL-2) expression in the murine T-cell line, EL4.IL2. J Biol Chem 271:13175-13183.
7. Dunnett C (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096-1121.
8. Faubert BL and Kaminski NE (2000) AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol 67:259-266.
9. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouboula M, Shire D, LeFur G, and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Pharmacol 232:54-61.
10. Gallichio MH, Conti DJ, Lempert N, Gruber SA, Geiselhart L, and Freed BM (1994) Calcium-mediated induction of anergy in the Jurkat T-cell line. Transplant Proc 26:3458-3459.
11. Glass M and Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333.
12. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM, Martin BR, and Abood ME (1999) Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377:117-125.
13. Harris NL and Ronchese F (1999) The role of B7 costimulation in T-cell immunity. Immunol Cell Biol 77:304-311.
14. Herring AC and Kaminski NE (1999) Cannabinol-mediated inhibition of nuclear factor-κB, cAMP response element-binding protein and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Ther 291:1156-1163.
15. Herring AC, Koh WS, and Kaminski NE (1998) Inhibition of the cAMP signaling cascade and nuclear factor binding to the CRE and κB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem Pharmacol 55:1013-1023.
16. Jan TR and Kaminski NE (2001) Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J Leukoc Biol 69:841-849.
17. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (Wash DC) 283:401-404.
18. Maier CC and Greene MI (1998) Biochemical features of anergic T cells. Immunol Res 17:133-140.
19. Maneuf YP and Brotchie JM (1997) Paradoxical action of the cannabinoid WIN 55, 212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398.
20. Matsuda LA (1997) Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 11:143-166.
21. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
22. McCoy KL, Matveyeva M, Carlisle SJ, and Cabral GA (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 289:1620-1625.
23. Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
24. Nakano Y, Pross SH, and Friedman H (1992) Modulation of interleukin 2 activity by delta-9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. Proc Soc Exp Biol Med 201:165-168.
25. Nakano Y, Pross S, and Friedman H (1993) Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in Spleen and lymph node cells of mice of different ages. Life Sci 52:41-51.
26. 2+/calmodulin kinase. Nature (Lond) 371:347-350.
27. Noe SN, Newton C, Widen R, Friedman H, and Klein TW (2000) Anti-CD40, anti-CD3 and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes. J Neuroimmunol 110:161-167.
28. Rinaldi-Carmona M, Barth F, Healume M, Shire D, Calandra B, Congy C, Martinez S, Aruani J, Neliat G, Caput D, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
29. Rinaldi-Carmona M, Barth F, Millna J, Deroeq J-M, Casellas P, Congy C, Oustric D, Sarrna M, Bouaboula M, Calandra B, et al. (1998) SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
30. Schatz AR, Lee M, Condie RB, Pulaski JT, and Kaminski NE (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142:278-287.
31. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, and Metters KM (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352-361.
32. Steiner H, Bonner TI, Zimmer AM, Kitai ST, and Zimmer A (1999) Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice [see comments]. Proc Natl Acad Sci USA 96:5786-5790.
33. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, Baba N, et al. (1999) Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues and related compounds. J Biol Chem 274:2794-2801.
34. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, and Waku K (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605-612.
35. Yea SS, Yang KH, and Kaminski NE (2000) Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther 292:597-605.
36. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, and Bonner TI (1999) Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785.
37. 2+ stores. Proc Natl Acad Sci USA 90:6295-6299.